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Introduction
Our understanding of the molecular mechanisms which orchestrate adipocyte differentiation have been greatly advanced by the use of preadipocytes cell lines, such as 3T3-L1 cells, capable of undergoing adipogenesis (14) . Upon reaching confluence, proliferating preadipocytes become growth arrested by contact inhibition. These growtharrested preadipocytes reenter the cell cycle after hormonal induction, arrest proliferation again, and finally undergo terminal adipocyte differentiation. The peroxisome proliferator-activated receptor γ (PPARγ), a ligand inducible transcription factor, has been identified as a major regulator of terminal adipocyte differentiation (10, 37). D-type cyclins were first characterized for their ability to coordinate cell cycle progression through the G1 phase. Three D cyclins (cyclins D1, D2, and D3) bind and activate cyclin dependent kinases 4/6 (CDK4/6), directing the phosphorylation of RB, as well as pRB related proteins p107 and p130. (4, 18, 28) . This phosphorylation event disrupts the pRB repressor complexes leading to derepression of E2F transcription factors and induction of E2F target genes which are required for S phase entry (6) .
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Cyclin D3 and adipogenesis Sarruf et al. 4 In addition to their defined role as part of the core cell cycle machinery, a new potential for D cyclins has emerged in other cellular processes including transcriptional control and differentiation. Cyclin D1 can bind and repress the activity of several transcription factors including b-Myb (15) , MyoD (34, 40) , and DMP1 (17) . Although less well explored, a CDK independent role for cyclin D3 has also been reported including inhibition of granulocyte differentiation (19) . More recent studies have attributed cyclin D3 with the ability to bind and activate certain transcription factors such as the human activating transcription factor 5 (hATF5) (25) . In the case of cyclin D3-/-mice it has been found that they fail to undergo development of immature T lymphocytes (39).
Recently our lab explored a link between the molecular processes governing adipocyte differentiation and the molecular machinery involved in cell cycle progression.
These studies have established key cell cycle regulators including the RB protein and the E2F transcription factor family as fundamental regulators of adipogenesis through their modulation of PPARγ expression and activity (9, 11) . Other recent studies have linked loss of cyclin dependent kinase inhibitors with obesity in mice (30) . The notion that adipogenesis is regulated by proteins of the cell cycle is not unexpected since early stages of 3T3-L1 adipogenesis (days 1-2) are marked by active rounds of mitotic clonal
expansion. An active cell cycle during the initial stages of adipogenesis is considered a prerequisite for terminal adipocyte differentiation (days 3-6) since CDK and MEK-1 (mitogen-activated protein kinase-1) inhibitors which prevent mitotic clonal expansion also block the differentiation process (41). Following a few rounds of mitotic division,
Cyclin D3 and adipogenesis
Sarruf et al.
5
CDK inhibitors mediate cell cycle exit which sets the stage for PPARγ driven terminal adipocyte differentiation (29) .
Because D-type cyclins represent a link between cell cycle progression, cell differentiation and transcriptional regulation, we wanted to explore their potential role during adipogenesis. We show here that cyclin D3 expression is up regulated during terminal stages of adipogenesis and functions as a ligand dependent coactivator of PPARγ capable of phosphorylating the A-B domain of the nuclear receptor. Knockdown of cyclin D3 diminished P P A R γ activity and adipogenesis whereas cyclin D3 overexpression had the opposite effect. Consistent with these findings we show that cyclin D3 null mice are protected from diet induced obesity, have reduced adipocyte size and increased sensitivity to insulin. 
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Materials and methods
Chemical reagents and antibodies. Pioglitazone was provided by Takeda Pharmaceutical Company (Osaka, Japan) and rosiglitazone was purchased from Interchim (Montlucon, France). All were purchased from Sigma (St. Louis, MI). Anticyclin D3 (sc-6283)), PPARγ (sc-7273), PPARγ (sc-7196), and actin (sc-1615) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The antiBrdU antibody was bought from Dako A/S (Glostrup, Denmark) Cell culture, transfections, and protein extracts. Cos and 3T3-L1 cells were grown in DMEM with 10% fetal bovine serum. In differentiation studies MDI (0.5 mM 3
Isobutyl-1-methylxanthine, 10 µg/ml insulin, and 1 µM dexamethasone) was added for 2 days. From day 3 on, 10 µg/ml insulin, and in certain cases 10 -6 M pioglitazone was added. Nuclear extracts and Oil Red O staining were prepared as described (35) expression vectors using Lipofectamine (Life technologies, Rockville, MD). Luciferase and β-gal activity was measured as described (35). Stable 3T3-L1 cell lines were carried out by transfection of the pcDNA3-cycD3 vector and the control empty vector followed by selection with neomycin (500µg/ml) for 15 days.
Pull-Down, Coimmunoprecipitation, and chromatin immunoprecipitation.
In-vitro translation of pSG5-PPARγ and pcDNA3-cycD3 was done using 35 S-methionine (Amersham, Orsay, France) in a TNT coupled reticulocyte lysate (promega, Madison, WI). Pull-down, immunoprecipitation assays were performed as described (9) . ChIP HAL author manuscript inserm-00144667, version 1 Samples were then subjected to SDS-PAGE electrophoresis, gels were then dried in a gel dryer for 1h at 80 °C and exposed to an X-ray film overnight.
Animal experiments. The cyclin D3 KO mice were a generous gift from P.
Sicinski with whom their generation has been previously described (39). Animals were maintained according to EU guidelines for use of laboratory animals. Sections from WAT were fixed in 4% formaldehyde and stained with H&E. IPGTT and insulin sensitivity tests were performed as described (33). Cyclin D3 -/-and age matched WT mice were fed a lipid rich diet (58% fat, 25% carbohydrates, and 16% protein) for 8
weeks. All experiments were performed with 6 age and gender matched mice for each group.
Results
Cyclin D3 expression is up-regulated during adipogenesis. When hormonally stimulated, confluent 3T3-L1 preadipocytes reenter the cell cycle before they undergo differentiation (14) . We correlated the expression of cyclin E, cyclin D3 and PPARγ during differentiation of 3T3-L1s. Protein levels of cyclin E were observed to increase after 1 day of differentiation coincident with cell cycle entry (Fig. 1A) . After 2 days of differentiation cyclin E expression drops as differentiating cells exit from the cell cycle and the expression of adipogenic markers such as PPARγ is switched on. (Fig. 1A) .
Surprisingly, cyclin D3 protein levels were undetectable during the early stages of differentiation and were strongly induced during later stages after the cells had already exited from the cell cycle and began to express PPARγ. A similar expression pattern was observed by immunofluorescence microscopy (Fig. 1B) . Interestingly we observed that cyclin D3 and PPARγ appeared to be co expressed in the same cells. To obtain further evidence of the expression pattern of cyclin D3 during adipogenesis we performed Northern blot analysis on differentiating 3T3-L1's. Such analysis revealed a potent increase in cyclin D3 mRNA throughout adipogenesis (Fig. 1C ). This result was confirmed by quantitative real time PCR analysis (qRT-PCR), which revealed a threefold increase in cyclin D3 mRNA throughout adipogenesis (Fig. 1D ). Consistent with protein expression (Fig 1A) , mRNA levels for cyclin E increase during days 1-2 and decreased thereafter, whereas expression of PPARγ increased strongly from day 1 through the end of differentiation. To determine the relative expression of cyclin D3
HAL author manuscript inserm-00144667, version 1 To determine whether cyclin D3 expression during adipogenesis was associated with an active cell cycle, we incubated differentiating 3T3-L1 cells with BrdU to mark proliferating cells. After a 24-hour incubation at day 5 of differentiation, cells were colabeled with Brdu and cyclin D3 antibodies and visualized by fluorescence microscopy.
We observed that only a limited percentage of cyclin D3 positive cells had incorporated BrdU (less than 12%) (Fig. 1F) . These results suggest a cell cycle independent role for cyclin D3 during adipogenesis.
Cyclin D3 inhibition impairs adipogenesis. To elucidate the role of cyclin D3
during adipogenesis, we silenced cyclin D3 expression using siRNA techniques. 3T3-L1
cell lines stably expressing a vector coding for a hairpin siRNA sequence against the mouse cyclin D3 transcript or an irrelevant siRNA were compared for their ability to differentiate into adipocytes. After 6 days in differentiation media, normal lipid accumulation was observed in control cells whereas a dramatic decrease in lipid accumulation was observed in cyclin D3 knockdown cells as assessed by Oil Red O staining ( Fig. 2A-B (Fig 3D) , further suggesting that cyclin D3 is an adipogenic factor.
Cyclin D3 stimulates PPARγ transcriptional activity. In light of our above observation showing co-expression of cyclin D3 and PPARγ in the same cells (Fig. 3D) ,
we decided to explore a potential functional relationship between the two proteins. To test whether cyclin D3's stimulatory role during adipogenesis may be mediated though activation of PPARγ, we performed cotransfection experiments using a PPARγ responsive, luciferase-based, reporter construct (PPRE-TK-Luc) and expression vectors for PPARγ2 and cyclin D3. A 3.5 fold induction of luciferase activity was observed upon transfection of PPARγ2 in the presence of the PPARγ agonist pioglitazone (Fig. 4A ).
This induction was further enhanced up to 5.5 fold by co-transfection of cyclin D3.
Transfection of cyclin D3 alone stimulated the PPARγ response element over two fold.
No effects of either PPARγ or cyclin D3 were observed on the parental reporter vector 13 TK-luc which does not contain a PPRE (Fig. 1A, right panel) . No induction of the PPRE-TK-Luc was observed after transfecting expression vectors coding for cyclin D1 and D2
(data not shown). We next tested whether the cotransfection of expression vectors coding for siRNA against cyclin D3 could attenuate the PPARγ mediated luciferase response.
Cotransfection of siRNA vector against cyclin D3 reduced PPARγ mediated luciferase activation by approximately 2 fold (Fig. 4B) . Together, these results suggest that cyclin D3's stimulatory role during adipogenesis is likely the result of its ability to modulate PPARγ activity.
Cyclin D3 physically interacts with PPARγ. To test whether the induction of
PPARγ activity in the presence of cyclin D3 is the consequence of an interaction between
PPARγ and cyclin D3, nuclear extracts from Cos cells transfected with cyclin D3 and
PPARγ expression vectors were immunoprecipitated with an anti-PPARγ antibody. A 33-kDa protein was recognized by a cyclin D3 antibody indicating that cyclin D3 is associated with P P A R γ (Fig. 5A, top panel) . We performed the same immunoprecipitation on endogenous PPARγ from differentiated 3T3L1's (day 5) and also revealed an association between the two proteins ( we performed the same pull-down assay in the presence and absence of the PPARγ 14 ligand rosiglitazone. Interestingly, we observed a strong enhancement of the interaction between cyclin D3 and DEF-PPARγ construct in the presence of rosiglitazone (Fig. 5C ).
To see if the ligand dependent interaction between cyclin D3 and PPARγ DEF could also be observed using full length. PPARγ, we incubated GST-cyclin D3 with full length invitro translated 35 S radiolabled PPARγ. We observed no interaction enhancement between cyclin D3 and PPARγ in the presence of ligand, (Fig. 5D) , possibly due to the masking of the ligand dependent effect by the additional contribution of the AB domain. We next set out to identify the region of cyclin D3 responsible for the interaction with PPARγ. Upon amino acid sequence screening of cyclin D3, we identified two LxxLL nuclear receptor interaction motifs located at the N and C terminal regions of the transcript (Fig. 5E ). To test the contribution of these LxxLL motifs on the interaction with PPARγ, we performed site specific mutagenesis converting the second L to I and performed GST pull down with purified full length PPARγ. Despite mutations of both LxxLL sites, the interaction with PPARγ was not disrupted indicating that these sites do not contribute to the interaction with PPARγ (Fig. 5E, lane 4) . Next, we created two deletion mutants of cyclin D3, Δ 1-149 which lacks the cyclin box (CDK binding unit), and deletion mutant Δ 148-293. GST pull-down assays reveal that amino-acid region 1-149 of cyclin D3 is required for the interaction with PPARγ (Fig. 5E ).
To demonstrate that cyclin D3 could regulate the expression of PPARγ target 
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(PPRE). Immunoprecipitation of cyclin D3 in the same conditions also resulted in amplification of the aP2 promoter (Fig. 5F, center panel) . No amplification of the aP2 promoter was observed when either PPARγ or cyclin D3 were immunoprecipitated from confluent , non-differentiated 3T3Ll cells which do not express PPARγ nor cyclin D3
( Fig 5F, top panel) . Binding of cyclin D3 and PPARγ was specific to the PPARγ binding site of the aP2 enhancer since no amplification was observed of a promoter region located outside the PPRE (Fig 5F, bottom panel) . To see if the recruitment of cyclin D3 to
PPARγ target genes is dependent on the presence of PPARγ, we performed additional ChIP experiments on NIH 3T3 cells, which do not express PPARγ, transfected or not with PPARγ2. We show that cyclin D3 is targeted to the PPRE of the aP2 promoter only when PPARγ is introduced into the cells by transfection (Fig. 5G) . The recruitment of cyclin D3 to the aP2 promoter was however not found to depend on ligand (data not shown). The results of these ChIP assays demonstrate that cyclin D3 is recruited to the promoter of PPARγ target genes during adipogenesis and that this recruitment is dependent on the presence of PPARγ.
The cyclin D3/CDK6 complex phosphorylates PPARγ. Because cyclin D3
together with its cyclin dependent kinase partners CDK4/6 constitutes an active kinase that phosphorylates RB during the cell cycle, we wanted to investigate whether cyclin D3
could also participate in PPARγ phosphorylation. To test this hypothesis we performed in-vitro kinase assays using an active cyclin D3/CDK6 kinase complex and purified
PPARγ protein as substrate. Kinase assays resulted in the apparition of a 60-kD band corresponding to the recombinant PPARγ molecular weight (Fig. 6A, lane 3) . As a control, the kinase assay was performed in the absence of active kinase or in the absence 16 of PPARγ (Fig. 6A lanes 1 and 2) . Next, to investigate which domain of PPARγ is phosphorylated by cylinD3/CDK6, we performed the same kinase assays on GST-PPARγ DEF and AB domains. The AB domain, but not the DEF domain was found to be phosphorylated by cyclinD3/CDK6 (Fig. 6B) . To further investigate the functional significance of the PPARγ-AB domain in the activation by cyclin D3, we performed cotransfection experiments using a chimeric gal4 PPARγ lacking the AB domain and whose activity is measured via the UAS-TK-Luc reporter construct. As expected, when chimeric gal4 PPARγ is introduced into the system in the presence of ligand, a strong induction of luciferase activity was observed. However, unlike experiments performed with full length PPARγ, cotransfection of cyclin D3 with PPARγ, failed to increase the luciferase response (Fig. 6C) . These results suggest that the AB domain of PPARγ is important for its activation by cyclin D3, possibly due the pressence of important phosphorylation sites. Next, to see if CDK6 could associate on the PPRE of the aP2 promoter and thereby contribute to the adipogenic process, we performed ChIP assays of CDK6 on differentiated 3T3L1s. PCR analysis of CDK6 immunoprecipitations confirmed its presence on the PPRE of the aP2 promoter (Fig. 6D ), further suggesting a role for CDK6 during adipogenesis.
Cyclin D3 null mice display a compromised adipose tissue phenotype. We have shown that cyclin D3 and PPARγ are expressed during the same time in the differentiation process and that cyclin D3 binds PPARγ and activates its transcriptional potential. To determine whether the activating effect of cyclin D3 could apply to in-vivo models, we analyzed the adipose tissue phenotype of cyclin D3 -/-mice. Cyclin D3 -/-mice showed normal weight gain and initial examination of fat tissue mass revealed no significant differences in weight between cyclin D3 -/-and WT mice (data not shown and Fig. 7A ). Histological analysis of epididymal fat pads uncovered that adipocytes from cyclin D3 -/-mice were significantly smaller than WT mice ( Fig. 7B and 7C ), suggesting that cyclin D3 is important for normal adipocyte differentiation. Interestingly this difference was observed in mice at five months of age but was absent in three-month old mice whose adipocytes were still of premature size in both cyclin D3 -/-and WT groups (data not shown). Gene expression analysis of white adipose tissue taken from five month old mice demonstrated a marked decrease in adipogenic markers aP2, LPL, and PPARγ (Fig. 7D) . We next analyzed the effect of challenging cyclin D3-/-mice with a high fat diet. After feeding the mice a lipid rich diet for 8 weeks, we observed a 30 % decrease in weight gain in cyclin D3-/-mice compared to their WT littermates (Fig. 7E) . Because adipocyte size is also known to affect glucose homeostasis, we measured both glucose tolerance and insulin sensitivity in cyclin D3 -/-mice. Initial glucose measurements indicated that cyclin D3 -/-mice have a 30% decrease in fasting glucose levels (Fig 7F) .
Intraperitoneal glucose tolerance test (IPGTT), revealed that cyclin D3 -/-cleared glucose more efficiently than WT mice (Fig. 7G) . Consistent with this observation, glucose decreased over two times more efficiently in cyclin D3 -/-compared to WT mice after insulin injection, indicating that the absence of cyclin D3 improves insulin sensitivity (Fig. 7H) . Taken together, these in-vivo studies confirm our in-vitro data and suggest a crucial role for cyclin D3 in adipose tissue development.
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Discussion
The results presented in this study establish a new role for cyclin D3 as a PPARγ co-factor. We show that cyclin D3 is preferentially expressed in adipose tissue and that its expression is strongly induced during terminal stages of 3T3-L1 adipogenesis. We have identified cyclin D3 as a PPARγ co-activator capable of phosphorylating its AB domain. The essential role that cyclin D3 plays during adipogenesis was highlighted by the observation that silencing its expression strongly inhibited adipogenesis whereas its over-expression promoted adipogenesis. Finally, we show that cyclin D3 -/-mice have a compromised adipose tissue phenotype. Our finding that cyclin D3 -/-mice display reduced adipocyte size, stunted adipogenic gene expression, resistance to high fat weight gain, and are insulin sensitive is reminiscent of the phenotype observed in PPARγ +/-mice (21). This observation is consistent with the hypothesis that the phenotype observed in cyclin D3 -/-mice is due to reduced PPARγ activity.
Over 20 years ago it was discovered how the ability of cyclins to bind and induce their CDK partners was dependent on their fluctuating expression pattern during the cell cycle (7). Here we show that the ability of cyclin D3 to bind PPARγ and help drive adipogenesis is also dependent on its differential expression pattern during adipogenesis.
Strikingly the stimulatory function of cyclin D3 during adipogenesis seems to fall deliberately outside its cell cycle role as evidenced by its protein expression pattern; cyclin D3 is almost undetectable during the mitotic clonal expansion phase of adipogenesis and then its expression is strongly induced during the non cycling terminal differentiation stage. Interestingly, an up regulation of cyclin D3 expression has also been 19 documented in other differentiation processes including during hematopoiesis (12, 26) and colon development (3) (incidentally PPARγ is also strongly induced during the later (23) . In the present study, we not only demonstrate an up regulation of cyclin D3 during adipocyte differentiation but also identify PPARγ as a functional partner through which cyclin D3 mediates its pro-adipogenic effects.
The stimulatory effects of cyclin D3 on PPARγ could be the direct result of phosphorylation of PPARγ (Fig. 4C) . 
